Overview:
We are excited to announce the 2nd Annual Paris Breast Cancer Conference™, a comprehensive educational conference designed to help you place emerging information into the context of landmark clinical trial data and established standards of care, with the goal of ultimately improving the care you provide to your patients with breast cancers.

This practical and interactive multiday program features a faculty of leading international experts who will provide up-to-date information and guidance via didactic lectures, question-and-answer sessions, and extended interactive, case-based panel discussions. This format will enable you to engage the faculty in a direct exchange of perspectives, personal experiences, and strategies related to your clinical challenges in the management of breast cancers.

This meeting is not to be missed!

Accreditation/Designation of Credit Information
This activity is provided by Physicians' Education Resource®, LLC. An application has been made to the EACCME® for CME accreditation of this event.

Registration Fees

<table>
<thead>
<tr>
<th>Physicist</th>
<th>Advance</th>
<th>On-Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complimentary Registration*</td>
<td>EUR 199</td>
<td>EUR 249</td>
</tr>
<tr>
<td>Nurses, PAs, Other Healthcare Professionals</td>
<td>EUR 199</td>
<td>EUR 249</td>
</tr>
<tr>
<td>Industry**</td>
<td>EUR 499</td>
<td>EUR 599</td>
</tr>
</tbody>
</table>

*Fellows registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

**Industry is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For registration assistance, please e-mail info@gotoper.com or call (609) 378-3701. A cancellation fee of 25% will be assessed on refunds requested prior to 5 October 2018, and a 50% fee on refunds requested on or after 6 October 2018. No refunds will be made after 27 October 2018. Substitutions can only be applied to the same conference. There is no charge for substitution. Substitutions must be accompanied by complimentary registration. Substitutions cannot be combined with other discounts/coupon codes.
Agenda

Friday, 16 November 2018

08:45  Breakfast
09:45  Welcome and Presession Survey

Early-Stage Triple-Negative Breast Cancer

09:55  Honing the Approach to Germline Alterations Assessment
10:15  Question & Answer
10:20  Who Should Receive Platinum-Based Chemotherapy?
10:40  Question & Answer
10:45  Challenging Case Debate: Early-Stage TNBC
11:30  Morning Break

Metastatic Triple-Negative Breast Cancer

11:55  Immunotherapeutics in TNBC
12:15  Question & Answer
12:20  PARP Inhibitors and Platinum Chemotherapy for Advanced BRCA-Related Cancer
12:40  Question & Answer
12:45  Lunch
13:40  Metastatic TNBC - New Treatments on the Horizon
14:00  Question & Answer
14:05  Challenging Case Debates: Metastatic TNBC
14:50  Postsession Survey

HER2-Positive Breast Cancer I

14:55  Presession Survey
15:00  Optimal Targeting of HER2 in the Early Setting
15:20  Question & Answer
15:25  Afternoon Break
15:50  New HER2-Targeting Therapies in the Advanced Setting
16:10  Question & Answer
16:15  Medical Crossfire®: Addressing the Challenges of Early HER2-Positive Breast Cancer
17:00  Postsession Survey
17:05  Adjourn
17:15  Networking Reception

Saturday, 17 November 2018

07:45  Breakfast

HER2-Positive Breast Cancer II

08:40  Welcome and Presession Survey
08:45  Maximizing Clinical Outcomes for Long-Term Responders
09:05  Question & Answer
09:10  New Therapeutic Approaches to Brain Metastases
09:30  Question & Answer
09:35  Challenging Case Debates: Metastatic HER2-Positive Breast Cancer
10:10  Postsession Survey

Early Luminal Breast Cancer

10:15  Presession Survey
10:20  Early-Stage Luminal Breast Cancer: Determining Relapse Risk
10:40  Question & Answer
10:45  Morning Break
11:10  Who Needs Extended Adjuvant Endocrine Therapy?
11:30  Question & Answer
11:35  Optimization of Neoadjuvant Endocrine Therapy
11:55  Question & Answer
12:00  Challenging Case Debate: Early Luminal Breast Cancer
12:45  Lunch

Treatment Considerations for Specific Patient Populations

13:45  Special Considerations for Older Patients
14:05  Special Considerations for Men

Metastatic Luminal Breast Cancer

14:25  Optimal Selection of CDK4/6 Inhibition
14:45  Question & Answer
14:50  Therapeutic Considerations for Patients Receiving Everolimus
15:10  Question & Answer
15:15  Mutation-Directed Therapy in ER-Positive Breast Cancer
15:35  Question & Answer
15:40  Medical Crossfire®: What Is the Best Treatment for Metastatic Luminal Breast Cancer?
16:10  Postsession Survey
16:15  Adjourn

*Agenda accurate at time of printing

To register visit gotoper.com/go/ECBC18BRO

An application has been made to the EACCME® for CME Accreditation of this event.

Faculty

Monica Arnedos, MD
Associate Professor, Department of Medical Oncology
Breast Cancer Unit
Gustave Roussy
Villejuif, France

Thomas Bachelot, MD, PhD
Director, Breast Cancer Unit
Centre Léon Bérard
Lyon, France

Judith Balmaña, MD, PhD
Head, Familial Cancer Unit
Assistant Breast Cancer Unit
Val d’Hebron University Hospital
Barcelona, Spain

Javier Cortés, MD, PhD
Head of the Breast Cancer and Gynecological Tumors
Ramón y Cajal University Hospital
Madrid, Spain
Clinical Investigator, Breast Cancer Research Program
Val d’Hebron Institute of Oncology
Barcelona, Spain

Alessandra Gennari, MD, PhD
Medical Director
Division of Medical Oncology
Galliera Hospital
Genoa, Italy

Prof. Sibylle Loibl
Co-Chair for the German Breast Group (GBG)
Professor
University of Frankfurt
Frankfurt, Germany

Christos Sotiriou, MD, PhD
Head - J.C. Heuson Breast Cancer Translational Research Laboratory
Institut Jules Bordet
Université Libre de Bruxelles
Brussels, Belgium

Inês Vaz-Luís, MD, MSc
Medical Oncologist, Molecular Medicine Department
Gustave Roussy
Villejuif, France